APO Research
Talk to an analyst

APO RESEARCH · REPORT

NGS for Cancer Early Screening

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global NGS for Cancer Early Screening Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

15 April 2026195 pages

Choose your research edition.

Industry ResearchNGS for Cancer Early Screening Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal NGS for Cancer Early Screening Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal NGS for Cancer Early Screening Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NGS for Cancer Early Screening Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal NGS for Cancer Early Screening Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global NGS for Cancer Early Screening market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for NGS for Cancer Early Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for NGS for Cancer Early Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for NGS for Cancer Early Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for NGS for Cancer Early Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of NGS for Cancer Early Screening include Guardant Health, Exact Sciences, Freenome, Epiginomics AG, Bio-techne, ThriveEarlier Detection, GRAIL, Inc., CellMax life and Berry Genomics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global NGS for Cancer Early Screening market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of NGS for Cancer Early Screening and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents NGS for Cancer Early Screening revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the NGS for Cancer Early Screening market size, projected growth trends, production technologies, key applications, and end-use industries.

NGS for Cancer Early Screening Segment by Company

Guardant Health

Exact Sciences

Freenome

Epiginomics AG

Bio-techne

ThriveEarlier Detection

GRAIL, Inc.

CellMax life

Berry Genomics

Singlera Genomics

Geneseeq

BGI Genomics

Burning Rock Biotech Limited

New Horizon Health Limited

Yeasen Bio

Hangzhou Aoru Biotech

Amoy Diagnostics Co., Ltd.

Genetron Health

AnchorDx

NGS for Cancer Early Screening Segment by Type

ctDNA Gene Mutation Detection

cfDNA Methylation Sequencing

NGS for Cancer Early Screening Segment by Application

Medical Institutions

Physical Examination Centers

NGS for Cancer Early Screening Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NGS for Cancer Early Screening market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NGS for Cancer Early Screening and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NGS for Cancer Early Screening.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of NGS for Cancer Early Screening in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global NGS for Cancer Early Screening industry.

Chapter 3: Detailed analysis of NGS for Cancer Early Screening companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, NGS for Cancer Early Screeningrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global NGS for Cancer Early Screening Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of ctDNA Gene Mutation Detection Table 3. Key Players of cfDNA Methylation Sequencing Table 4. Global NGS for Cancer Early Screening Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 5. Key Players of Medical Institutions Table 6. Key Players of Physical Examination Centers Table 7. Global NGS for Cancer Early Screening Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 8. Global NGS for Cancer Early Screening Market Size by Region (2021-2026) & (US$ Million) Table 9. Global NGS for Cancer Early Screening Market Share by Region (2021-2026) Table 10. Global NGS for Cancer Early Screening Market Size by Region (2027-2032) & (US$ Million) Table 11. Global NGS for Cancer Early Screening Market Share by Region (2027-2032) Table 12. NGS for Cancer Early Screening Industry Trends Table 13. NGS for Cancer Early Screening Industry Drivers Table 14. NGS for Cancer Early Screening Industry Opportunities and Challenges Table 15. NGS for Cancer Early Screening Industry Restraints Table 16. Global NGS for Cancer Early Screening Revenue by Company (US$ Million) & (2021-2026) Table 17. Global NGS for Cancer Early Screening Revenue Market Share by Company (2021-2026) Table 18. Global NGS for Cancer Early Screening Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 19. Global NGS for Cancer Early Screening Key Company Head Office and Area Served Table 20. Global NGS for Cancer Early Screening Company, Product Type & Application Table 21. Global NGS for Cancer Early Screening Company Establishment Date Table 22. Global Company Market Concentration Ratio (CR5 and HHI) Table 23. Global NGS for Cancer Early Screening by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 24. Global NGS for Cancer Early Screening Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global NGS for Cancer Early Screening Market Size by Type (2021-2026) & (US$ Million) Table 26. Global NGS for Cancer Early Screening Market Size by Type (2027-2032) & (US$ Million) Table 27. Global NGS for Cancer Early Screening Revenue Market Share by Type (2021-2026) Table 28. Global NGS for Cancer Early Screening Revenue Market Share by Type (2027-2032) Table 29. Global NGS for Cancer Early Screening Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global NGS for Cancer Early Screening Market Size by Application (2021-2026) & (US$ Million) Table 31. Global NGS for Cancer Early Screening Market Size by Application (2027-2032) & (US$ Million) Table 32. Global NGS for Cancer Early Screening Revenue Market Share by Application (2021-2026) Table 33. Global NGS for Cancer Early Screening Revenue Market Share by Application (2027-2032) Table 34. Guardant Health Company Information Table 35. Guardant Health Business Overview Table 36. Guardant Health NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Guardant Health NGS for Cancer Early Screening Product Portfolio Table 38. Guardant Health Recent Development Table 39. Exact Sciences Company Information Table 40. Exact Sciences Business Overview Table 41. Exact Sciences NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Exact Sciences NGS for Cancer Early Screening Product Portfolio Table 43. Exact Sciences Recent Development Table 44. Freenome Company Information Table 45. Freenome Business Overview Table 46. Freenome NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Freenome NGS for Cancer Early Screening Product Portfolio Table 48. Freenome Recent Development Table 49. Epiginomics AG Company Information Table 50. Epiginomics AG Business Overview Table 51. Epiginomics AG NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Epiginomics AG NGS for Cancer Early Screening Product Portfolio Table 53. Epiginomics AG Recent Development Table 54. Bio-techne Company Information Table 55. Bio-techne Business Overview Table 56. Bio-techne NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Bio-techne NGS for Cancer Early Screening Product Portfolio Table 58. Bio-techne Recent Development Table 59. ThriveEarlier Detection Company Information Table 60. ThriveEarlier Detection Business Overview Table 61. ThriveEarlier Detection NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. ThriveEarlier Detection NGS for Cancer Early Screening Product Portfolio Table 63. ThriveEarlier Detection Recent Development Table 64. GRAIL, Inc. Company Information Table 65. GRAIL, Inc. Business Overview Table 66. GRAIL, Inc. NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. GRAIL, Inc. NGS for Cancer Early Screening Product Portfolio Table 68. GRAIL, Inc. Recent Development Table 69. CellMax life Company Information Table 70. CellMax life Business Overview Table 71. CellMax life NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. CellMax life NGS for Cancer Early Screening Product Portfolio Table 73. CellMax life Recent Development Table 74. Berry Genomics Company Information Table 75. Berry Genomics Business Overview Table 76. Berry Genomics NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Berry Genomics NGS for Cancer Early Screening Product Portfolio Table 78. Berry Genomics Recent Development Table 79. Singlera Genomics Company Information Table 80. Singlera Genomics Business Overview Table 81. Singlera Genomics NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Singlera Genomics NGS for Cancer Early Screening Product Portfolio Table 83. Singlera Genomics Recent Development Table 84. Geneseeq Company Information Table 85. Geneseeq Business Overview Table 86. Geneseeq NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Geneseeq NGS for Cancer Early Screening Product Portfolio Table 88. Geneseeq Recent Development Table 89. BGI Genomics Company Information Table 90. BGI Genomics Business Overview Table 91. BGI Genomics NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 92. BGI Genomics NGS for Cancer Early Screening Product Portfolio Table 93. BGI Genomics Recent Development Table 94. Burning Rock Biotech Limited Company Information Table 95. Burning Rock Biotech Limited Business Overview Table 96. Burning Rock Biotech Limited NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 97. Burning Rock Biotech Limited NGS for Cancer Early Screening Product Portfolio Table 98. Burning Rock Biotech Limited Recent Development Table 99. New Horizon Health Limited Company Information Table 100. New Horizon Health Limited Business Overview Table 101. New Horizon Health Limited NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 102. New Horizon Health Limited NGS for Cancer Early Screening Product Portfolio Table 103. New Horizon Health Limited Recent Development Table 104. Yeasen Bio Company Information Table 105. Yeasen Bio Business Overview Table 106. Yeasen Bio NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 107. Yeasen Bio NGS for Cancer Early Screening Product Portfolio Table 108. Yeasen Bio Recent Development Table 109. Hangzhou Aoru Biotech Company Information Table 110. Hangzhou Aoru Biotech Business Overview Table 111. Hangzhou Aoru Biotech NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 112. Hangzhou Aoru Biotech NGS for Cancer Early Screening Product Portfolio Table 113. Hangzhou Aoru Biotech Recent Development Table 114. Amoy Diagnostics Co., Ltd. Company Information Table 115. Amoy Diagnostics Co., Ltd. Business Overview Table 116. Amoy Diagnostics Co., Ltd. NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 117. Amoy Diagnostics Co., Ltd. NGS for Cancer Early Screening Product Portfolio Table 118. Amoy Diagnostics Co., Ltd. Recent Development Table 119. Genetron Health Company Information Table 120. Genetron Health Business Overview Table 121. Genetron Health NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 122. Genetron Health NGS for Cancer Early Screening Product Portfolio Table 123. Genetron Health Recent Development Table 124. AnchorDx Company Information Table 125. AnchorDx Business Overview Table 126. AnchorDx NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026) Table 127. AnchorDx NGS for Cancer Early Screening Product Portfolio Table 128. AnchorDx Recent Development Table 129. North America NGS for Cancer Early Screening Market Size by Type (2021-2026) & (US$ Million) Table 130. North America NGS for Cancer Early Screening Market Size by Type (2027-2032) & (US$ Million) Table 131. North America NGS for Cancer Early Screening Market Size by Application (2021-2026) & (US$ Million) Table 132. North America NGS for Cancer Early Screening Market Size by Application (2027-2032) & (US$ Million) Table 133. North America NGS for Cancer Early Screening Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 134. North America NGS for Cancer Early Screening Market Size by Country (2021-2026) Table 135. North America NGS for Cancer Early Screening Market Size by Country (2027-2032) Table 136. Europe NGS for Cancer Early Screening Market Size by Type (2021-2026) & (US$ Million) Table 137. Europe NGS for Cancer Early Screening Market Size by Type (2027-2032) & (US$ Million) Table 138. Europe NGS for Cancer Early Screening Market Size by Application (2021-2026) & (US$ Million) Table 139. Europe NGS for Cancer Early Screening Market Size by Application (2027-2032) & (US$ Million) Table 140. Europe NGS for Cancer Early Screening Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 141. Europe NGS for Cancer Early Screening Market Size by Country (2021-2026) Table 142. Europe NGS for Cancer Early Screening Market Size by Country (2027-2032) Table 143. China NGS for Cancer Early Screening Market Size by Type (2021-2026) & (US$ Million) Table 144. China NGS for Cancer Early Screening Market Size by Type (2027-2032) & (US$ Million) Table 145. China NGS for Cancer Early Screening Market Size by Application (2021-2026) & (US$ Million) Table 146. China NGS for Cancer Early Screening Market Size by Application (2027-2032) & (US$ Million) Table 147. Asia NGS for Cancer Early Screening Market Size by Type (2021-2026) & (US$ Million) Table 148. Asia NGS for Cancer Early Screening Market Size by Type (2027-2032) & (US$ Million) Table 149. Asia NGS for Cancer Early Screening Market Size by Application (2021-2026) & (US$ Million) Table 150. Asia NGS for Cancer Early Screening Market Size by Application (2027-2032) & (US$ Million) Table 151. Asia NGS for Cancer Early Screening Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 152. Asia NGS for Cancer Early Screening Market Size by Country (2021-2026) Table 153. Asia NGS for Cancer Early Screening Market Size by Country (2027-2032) Table 154. South America, Middle East & Africa NGS for Cancer Early Screening Market Size by Type (2021-2026) & (US$ Million) Table 155. South America, Middle East & Africa NGS for Cancer Early Screening Market Size by Type (2027-2032) & (US$ Million) Table 156. South America, Middle East & Africa NGS for Cancer Early Screening Market Size by Application (2021-2026) & (US$ Million) Table 157. South America, Middle East & Africa NGS for Cancer Early Screening Market Size by Application (2027-2032) & (US$ Million) Table 158. South America, Middle East & Africa NGS for Cancer Early Screening Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 159. South America, Middle East & Africa NGS for Cancer Early Screening Market Size by Country (2021-2026) Table 160. South America, Middle East & Africa NGS for Cancer Early Screening Market Size by Country (2027-2032) Table 161. Research Programs/Design for This Report Table 162. Authors List of This Report Table 163. Secondary Sources Table 164. Primary Sources List of Figures Figure 1. NGS for Cancer Early Screening Product Image Figure 2. Global NGS for Cancer Early Screening Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global NGS for Cancer Early Screening Market Share by Type: 2025 VS 2032 Figure 4. ctDNA Gene Mutation Detection Image Figure 5. cfDNA Methylation Sequencing Image Figure 6. Global NGS for Cancer Early Screening Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 7. Global NGS for Cancer Early Screening Market Share by Application: 2025 VS 2032 Figure 8. Medical Institutions Image Figure 9. Physical Examination Centers Image Figure 10. Global NGS for Cancer Early Screening Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 12. Global NGS for Cancer Early Screening Market Share by Region: 2025 VS 2032 Figure 13. Years Considered Figure 14. Global NGS for Cancer Early Screening Market Share by Players in 2025 Figure 15. Global Top 5 and 10 NGS for Cancer Early Screening Players Market Share by Revenue in 2025 Figure 16. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global NGS for Cancer Early Screening Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global NGS for Cancer Early Screening Revenue Market Share by Type (2021-2032) Figure 19. Global NGS for Cancer Early Screening Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global NGS for Cancer Early Screening Revenue Market Share by Application (2021-2032) Figure 21. North America NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 22. North America NGS for Cancer Early Screening Market Share by Type (2021-2032) Figure 23. North America NGS for Cancer Early Screening Market Share by Application (2021-2032) Figure 24. North America NGS for Cancer Early Screening Market Share by Country (2021-2032) Figure 25. United States NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 26. Canada NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 27. Mexico NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 28. Europe NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 29. Europe NGS for Cancer Early Screening Market Share by Type (2021-2032) Figure 30. Europe NGS for Cancer Early Screening Market Share by Application (2021-2032) Figure 31. Europe NGS for Cancer Early Screening Market Share by Country (2021-2032) Figure 32. Germany NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 33. France NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 34. U.K. NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 35. Italy NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 36. Russia NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 37. Nordic Countries NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 38. China NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 39. China NGS for Cancer Early Screening Market Share by Type (2021-2032) Figure 40. China NGS for Cancer Early Screening Market Share by Application (2021-2032) Figure 41. Asia NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 42. Asia NGS for Cancer Early Screening Market Share by Type (2021-2032) Figure 43. Asia NGS for Cancer Early Screening Market Share by Application (2021-2032) Figure 44. Asia NGS for Cancer Early Screening Market Share by Country (2021-2032) Figure 45. Japan NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 46. South Korea NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 47. Taiwan NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 48. Southeast Asia NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 49. India NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 50. Australia NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 51. South America, Middle East & Africa NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 52. South America, Middle East & Africa NGS for Cancer Early Screening Market Share by Type (2021-2032) Figure 53. South America, Middle East & Africa NGS for Cancer Early Screening Market Share by Application (2021-2032) Figure 54. South America, Middle East & Africa NGS for Cancer Early Screening Market Share by Country (2021-2032) Figure 55. Brazil NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 56. South Africa NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 57. Saudi Arabia NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 58. Turkey NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 59. Argentina NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 60. UAE NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 61. Egypt NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 62. Chile NGS for Cancer Early Screening Market Size (2021-2032) & (US$ Million) Figure 63. Research Process Figure 64. Key Executives Interviewed

Scope & coverage.

Types
  • ctDNA Gene Mutation Detection
  • cfDNA Methylation Sequencing
Applications
  • Medical Institutions
  • Physical Examination Centers
Companies covered
  • Guardant Health
  • Exact Sciences
  • Freenome
  • Epiginomics AG
  • Bio-techne
  • ThriveEarlier Detection
  • GRAIL, Inc.
  • CellMax life
  • Berry Genomics
  • Singlera Genomics
  • Geneseeq
  • BGI Genomics
  • Burning Rock Biotech Limited
  • New Horizon Health Limited
  • Yeasen Bio
  • Hangzhou Aoru Biotech
  • Amoy Diagnostics Co., Ltd.
  • Genetron Health
  • AnchorDx

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global NGS for Cancer Early Screening Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 ctDNA Gene Mutation Detection
  5. 1.2.3 cfDNA Methylation Sequencing
  6. 1.3 Market Analysis by Application
  7. 1.3.1 Global NGS for Cancer Early Screening Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  8. 1.3.2 Medical Institutions
  9. 1.3.3 Physical Examination Centers
  10. 1.4 Global Market Growth Prospects
  11. 1.5 Global NGS for Cancer Early Screening Growth Trends by Region
  12. 1.5.1 Global NGS for Cancer Early Screening Market Size by Region: 2021 VS 2025 VS 2032
  13. 1.5.2 NGS for Cancer Early Screening Market Size by Region (2021-2026)
  14. 1.5.3 NGS for Cancer Early Screening Market Size by Region (2027-2032)
  15. 1.6 Assumptions and Limitations
  16. 1.7 Study Goals and Objectives
  17. 1.8 Years Considered
2 Global NGS for Cancer Early Screening Market Dynamics
  1. 2.1 NGS for Cancer Early Screening Industry Trends
  2. 2.2 NGS for Cancer Early Screening Industry Drivers
  3. 2.3 NGS for Cancer Early Screening Industry Opportunities and Challenges
  4. 2.4 NGS for Cancer Early Screening Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global NGS for Cancer Early Screening Revenue by Company (2021-2026)
  2. 3.2 Global NGS for Cancer Early Screening Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global NGS for Cancer Early Screening Key Company Head office and Area Served
  4. 3.4 Global NGS for Cancer Early Screening Company, Product Type & Application
  5. 3.5 Global NGS for Cancer Early Screening Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global NGS for Cancer Early Screening Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 NGS for Cancer Early Screening Players Market Share by Revenue in 2025
  9. 3.6.3 2025 NGS for Cancer Early Screening Tier 1, Tier 2, and Tier 3
4 NGS for Cancer Early Screening Market by Type
  1. 4.1 Global NGS for Cancer Early Screening Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global NGS for Cancer Early Screening Market Size by Type (2021-2032)
  3. 4.3 Global NGS for Cancer Early Screening Market Size Share by Type (2021-2032)
5 NGS for Cancer Early Screening Market by Application
  1. 5.1 Global NGS for Cancer Early Screening Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global NGS for Cancer Early Screening Market Size by Application (2021-2032)
  3. 5.3 Global NGS for Cancer Early Screening Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Guardant Health
  2. 6.1.1 Guardant Health Company Information
  3. 6.1.2 Guardant Health Business Overview
  4. 6.1.3 Guardant Health NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Guardant Health NGS for Cancer Early Screening Product Portfolio
  6. 6.1.5 Guardant Health Recent Developments
  7. 6.2 Exact Sciences
  8. 6.2.1 Exact Sciences Company Information
  9. 6.2.2 Exact Sciences Business Overview
  10. 6.2.3 Exact Sciences NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Exact Sciences NGS for Cancer Early Screening Product Portfolio
  12. 6.2.5 Exact Sciences Recent Developments
  13. 6.3 Freenome
  14. 6.3.1 Freenome Company Information
  15. 6.3.2 Freenome Business Overview
  16. 6.3.3 Freenome NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Freenome NGS for Cancer Early Screening Product Portfolio
  18. 6.3.5 Freenome Recent Developments
  19. 6.4 Epiginomics AG
  20. 6.4.1 Epiginomics AG Company Information
  21. 6.4.2 Epiginomics AG Business Overview
  22. 6.4.3 Epiginomics AG NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Epiginomics AG NGS for Cancer Early Screening Product Portfolio
  24. 6.4.5 Epiginomics AG Recent Developments
  25. 6.5 Bio-techne
  26. 6.5.1 Bio-techne Company Information
  27. 6.5.2 Bio-techne Business Overview
  28. 6.5.3 Bio-techne NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Bio-techne NGS for Cancer Early Screening Product Portfolio
  30. 6.5.5 Bio-techne Recent Developments
  31. 6.6 ThriveEarlier Detection
  32. 6.6.1 ThriveEarlier Detection Company Information
  33. 6.6.2 ThriveEarlier Detection Business Overview
  34. 6.6.3 ThriveEarlier Detection NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 ThriveEarlier Detection NGS for Cancer Early Screening Product Portfolio
  36. 6.6.5 ThriveEarlier Detection Recent Developments
  37. 6.7 GRAIL, Inc.
  38. 6.7.1 GRAIL, Inc. Company Information
  39. 6.7.2 GRAIL, Inc. Business Overview
  40. 6.7.3 GRAIL, Inc. NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 GRAIL, Inc. NGS for Cancer Early Screening Product Portfolio
  42. 6.7.5 GRAIL, Inc. Recent Developments
  43. 6.8 CellMax life
  44. 6.8.1 CellMax life Company Information
  45. 6.8.2 CellMax life Business Overview
  46. 6.8.3 CellMax life NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 CellMax life NGS for Cancer Early Screening Product Portfolio
  48. 6.8.5 CellMax life Recent Developments
  49. 6.9 Berry Genomics
  50. 6.9.1 Berry Genomics Company Information
  51. 6.9.2 Berry Genomics Business Overview
  52. 6.9.3 Berry Genomics NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Berry Genomics NGS for Cancer Early Screening Product Portfolio
  54. 6.9.5 Berry Genomics Recent Developments
  55. 6.10 Singlera Genomics
  56. 6.10.1 Singlera Genomics Company Information
  57. 6.10.2 Singlera Genomics Business Overview
  58. 6.10.3 Singlera Genomics NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Singlera Genomics NGS for Cancer Early Screening Product Portfolio
  60. 6.10.5 Singlera Genomics Recent Developments
  61. 6.11 Geneseeq
  62. 6.11.1 Geneseeq Company Information
  63. 6.11.2 Geneseeq Business Overview
  64. 6.11.3 Geneseeq NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Geneseeq NGS for Cancer Early Screening Product Portfolio
  66. 6.11.5 Geneseeq Recent Developments
  67. 6.12 BGI Genomics
  68. 6.12.1 BGI Genomics Company Information
  69. 6.12.2 BGI Genomics Business Overview
  70. 6.12.3 BGI Genomics NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 BGI Genomics NGS for Cancer Early Screening Product Portfolio
  72. 6.12.5 BGI Genomics Recent Developments
  73. 6.13 Burning Rock Biotech Limited
  74. 6.13.1 Burning Rock Biotech Limited Company Information
  75. 6.13.2 Burning Rock Biotech Limited Business Overview
  76. 6.13.3 Burning Rock Biotech Limited NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Burning Rock Biotech Limited NGS for Cancer Early Screening Product Portfolio
  78. 6.13.5 Burning Rock Biotech Limited Recent Developments
  79. 6.14 New Horizon Health Limited
  80. 6.14.1 New Horizon Health Limited Company Information
  81. 6.14.2 New Horizon Health Limited Business Overview
  82. 6.14.3 New Horizon Health Limited NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 New Horizon Health Limited NGS for Cancer Early Screening Product Portfolio
  84. 6.14.5 New Horizon Health Limited Recent Developments
  85. 6.15 Yeasen Bio
  86. 6.15.1 Yeasen Bio Company Information
  87. 6.15.2 Yeasen Bio Business Overview
  88. 6.15.3 Yeasen Bio NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Yeasen Bio NGS for Cancer Early Screening Product Portfolio
  90. 6.15.5 Yeasen Bio Recent Developments
  91. 6.16 Hangzhou Aoru Biotech
  92. 6.16.1 Hangzhou Aoru Biotech Company Information
  93. 6.16.2 Hangzhou Aoru Biotech Business Overview
  94. 6.16.3 Hangzhou Aoru Biotech NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 Hangzhou Aoru Biotech NGS for Cancer Early Screening Product Portfolio
  96. 6.16.5 Hangzhou Aoru Biotech Recent Developments
  97. 6.17 Amoy Diagnostics Co., Ltd.
  98. 6.17.1 Amoy Diagnostics Co., Ltd. Company Information
  99. 6.17.2 Amoy Diagnostics Co., Ltd. Business Overview
  100. 6.17.3 Amoy Diagnostics Co., Ltd. NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 Amoy Diagnostics Co., Ltd. NGS for Cancer Early Screening Product Portfolio
  102. 6.17.5 Amoy Diagnostics Co., Ltd. Recent Developments
  103. 6.18 Genetron Health
  104. 6.18.1 Genetron Health Company Information
  105. 6.18.2 Genetron Health Business Overview
  106. 6.18.3 Genetron Health NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 Genetron Health NGS for Cancer Early Screening Product Portfolio
  108. 6.18.5 Genetron Health Recent Developments
  109. 6.19 AnchorDx
  110. 6.19.1 AnchorDx Company Information
  111. 6.19.2 AnchorDx Business Overview
  112. 6.19.3 AnchorDx NGS for Cancer Early Screening Revenue and Gross Margin (US$ Million) & (2021-2026)
  113. 6.19.4 AnchorDx NGS for Cancer Early Screening Product Portfolio
  114. 6.19.5 AnchorDx Recent Developments
7 North America
  1. 7.1 North America NGS for Cancer Early Screening Market Size (2021-2032)
  2. 7.2 North America NGS for Cancer Early Screening Market Size by Type
  3. 7.2.1 North America NGS for Cancer Early Screening Market Size by Type (2021-2026)
  4. 7.2.2 North America NGS for Cancer Early Screening Market Size by Type (2027-2032)
  5. 7.2.3 North America NGS for Cancer Early Screening Market Share by Type (2021-2032)
  6. 7.3 North America NGS for Cancer Early Screening Market Size by Application
  7. 7.3.1 North America NGS for Cancer Early Screening Market Size by Application (2021-2026)
  8. 7.3.2 North America NGS for Cancer Early Screening Market Size by Application (2027-2032)
  9. 7.3.3 North America NGS for Cancer Early Screening Market Share by Application (2021-2032)
  10. 7.4 North America NGS for Cancer Early Screening Market Size by Country
  11. 7.4.1 North America NGS for Cancer Early Screening Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America NGS for Cancer Early Screening Market Size by Country (2021-2026)
  13. 7.4.3 North America NGS for Cancer Early Screening Market Size by Country (2027-2032)
  14. 7.4.4 North America NGS for Cancer Early Screening Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe NGS for Cancer Early Screening Market Size (2021-2032)
  2. 8.2 Europe NGS for Cancer Early Screening Market Size by Type
  3. 8.2.1 Europe NGS for Cancer Early Screening Market Size by Type (2021-2026)
  4. 8.2.2 Europe NGS for Cancer Early Screening Market Size by Type (2027-2032)
  5. 8.2.3 Europe NGS for Cancer Early Screening Market Share by Type (2021-2032)
  6. 8.3 Europe NGS for Cancer Early Screening Market Size by Application
  7. 8.3.1 Europe NGS for Cancer Early Screening Market Size by Application (2021-2026)
  8. 8.3.2 Europe NGS for Cancer Early Screening Market Size by Application (2027-2032)
  9. 8.3.3 Europe NGS for Cancer Early Screening Market Share by Application (2021-2032)
  10. 8.4 Europe NGS for Cancer Early Screening Market Size by Country
  11. 8.4.1 Europe NGS for Cancer Early Screening Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe NGS for Cancer Early Screening Market Size by Country (2021-2026)
  13. 8.4.3 Europe NGS for Cancer Early Screening Market Size by Country (2027-2032)
  14. 8.4.4 Europe NGS for Cancer Early Screening Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China NGS for Cancer Early Screening Market Size (2021-2032)
  2. 9.2 China NGS for Cancer Early Screening Market Size by Type
  3. 9.2.1 China NGS for Cancer Early Screening Market Size by Type (2021-2026)
  4. 9.2.2 China NGS for Cancer Early Screening Market Size by Type (2027-2032)
  5. 9.2.3 China NGS for Cancer Early Screening Market Share by Type (2021-2032)
  6. 9.3 China NGS for Cancer Early Screening Market Size by Application
  7. 9.3.1 China NGS for Cancer Early Screening Market Size by Application (2021-2026)
  8. 9.3.2 China NGS for Cancer Early Screening Market Size by Application (2027-2032)
  9. 9.3.3 China NGS for Cancer Early Screening Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia NGS for Cancer Early Screening Market Size (2021-2032)
  2. 10.2 Asia NGS for Cancer Early Screening Market Size by Type
  3. 10.2.1 Asia NGS for Cancer Early Screening Market Size by Type (2021-2026)
  4. 10.2.2 Asia NGS for Cancer Early Screening Market Size by Type (2027-2032)
  5. 10.2.3 Asia NGS for Cancer Early Screening Market Share by Type (2021-2032)
  6. 10.3 Asia NGS for Cancer Early Screening Market Size by Application
  7. 10.3.1 Asia NGS for Cancer Early Screening Market Size by Application (2021-2026)
  8. 10.3.2 Asia NGS for Cancer Early Screening Market Size by Application (2027-2032)
  9. 10.3.3 Asia NGS for Cancer Early Screening Market Share by Application (2021-2032)
  10. 10.4 Asia NGS for Cancer Early Screening Market Size by Country
  11. 10.4.1 Asia NGS for Cancer Early Screening Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia NGS for Cancer Early Screening Market Size by Country (2021-2026)
  13. 10.4.3 Asia NGS for Cancer Early Screening Market Size by Country (2027-2032)
  14. 10.4.4 Asia NGS for Cancer Early Screening Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa NGS for Cancer Early Screening Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa NGS for Cancer Early Screening Market Size by Type
  3. 11.2.1 South America, Middle East & Africa NGS for Cancer Early Screening Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa NGS for Cancer Early Screening Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa NGS for Cancer Early Screening Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa NGS for Cancer Early Screening Market Size by Application
  7. 11.3.1 South America, Middle East & Africa NGS for Cancer Early Screening Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa NGS for Cancer Early Screening Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa NGS for Cancer Early Screening Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa NGS for Cancer Early Screening Market Size by Country
  11. 11.4.1 South America, Middle East & Africa NGS for Cancer Early Screening Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa NGS for Cancer Early Screening Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa NGS for Cancer Early Screening Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa NGS for Cancer Early Screening Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst